Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers

NCT01720212 is registered in ClinicalTrials.gov with Astellas Pharma China, Inc. as lead sponsor.

NCT NCT01720212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01720212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers
Lead sponsor
Astellas Pharma China, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2012
Completion date
August 31, 2012
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy chinese volunteers